KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer

Biomark Med. 2024;18(10-12):509-510. doi: 10.1080/17520363.2024.2352409. Epub 2024 Jun 17.

Pauline Corbaux^{1

2}, Olivier Colomban¹, Aurore Carrot¹, Benoit You^{1

3}

¹ EA UCBL/HCL 3738, Centre pour l'lnnovation en Cancérologie de Lyon (CICLY), Faculty of Medicine Lyon-Sud, Claude Bernard University Lyon 1, Oullins-Pierre-Bénite, 69921, France.
² Medical Oncology, Institut de Cancérologie et d'Hématologie Universitaire de Saint-Étienne (ICHUSE), Centre Hospitalier Universitaire de Saint-Etienne, Saint-Priest-en-Jarez, 42270, France.
³ Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, Centre Hospitalier Lyon-Sud, Oullins-Pierre-Bénite, 69495, France.

No abstract available

Keywords: CA-125; KELIM; ovarian cancer; primary chemosensitivity; prognostic biomarker.

Publication types